Ocker, I'll see your EXCEPT and raise you another EXCEPT:
To compare MCP's P/E today to its P/E over the past years is to compare apples with oranges. The inconsistency lies in the small matter of the differential capital structure.
Simply and crudely: MCP's EV today is around $265m ($200m market cap and ~$65m in average net debt for FY11). For the bulk of the 2000 to 2010 period, MCP's Net Debt averaged ~$120m, implying an EV (even at today's expanded issued share capital) of $320m.
At an EV of $320m, a P/E of 7.5x translates into an EV/EBITDA multiple of 6.2x (you can do the rudimentary arithmetic yourself; I've omitted it in the interests of brevity). Yet, at MCP's capital structure today, the EV/EBITDA at the same 7.5x P/E multiple is only 5.1 times.
(again, basic Excel spreadsheet workings will confirm this to be a mathematical axiom)
So, to get MCP to its long-term EV/EBITDA multiple implies around 30% equity valuation uplift.
At the risk of labouring the point, assume - as I do when investing in businesses - that you are to own, not just a share of the company, but the entire enterprise. Assume, too - as you should - that you look to minimise the period over which you recoup your outlay to purchase the enterprise in question.
In MCP's case, the business generates free cash flow of around $25m to $26m per annum. That puts the business on a FCF yield of:
8% based on an EV of $320m (12.3 year payback period), or
10% based on an EV of $260m (10 year payback period)
And that's the problem with the vanilla P/E multiple as a valuation tool; it fails to account for the important fact that not all "E"'s are created equal.
Hope you don't think me presumptious, but I thought I'd highlight what I believe to be some flawed logic in the unilateral application of P/E's. They're nice and quick, but the trade-off in their use is incomprehensiveness (is that a word?).
Regards and Prudent Investing
Cameron
PS. Without wanting to be overly pedantic, if you do insist on valuing MCP using a P/E multiple based on FY10 EPS, then be advised that underlying EPS for the year was 37.2cps, as distinct from the reported figure of 36.2cps (the difference being a $0.7m restructuring charge taken to account in JH10). But as I have admitted, it's somewhat of a matter of pedantry.
- Forums
- ASX - By Stock
- mcp under valued by 40%
MCP
mcpherson's limited
Add to My Watchlist
0.00%
!
23.0¢

Ocker, I'll see your EXCEPT and raise you another EXCEPT:To...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
23.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.10M |
Open | High | Low | Value | Volume |
23.0¢ | 23.5¢ | 23.0¢ | $2.493M | 10.83M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 22 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 6329 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 22 | 0.230 |
2 | 30444 | 0.225 |
3 | 26000 | 0.220 |
1 | 4760 | 0.210 |
5 | 50460 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 6329 | 1 |
0.240 | 160999 | 7 |
0.245 | 10000 | 1 |
0.250 | 16900 | 2 |
0.270 | 24085 | 3 |
Last trade - 14.34pm 18/06/2025 (20 minute delay) ? |
Featured News
MCP (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online